Comparison of roxatidine and ranitidine in the treatment of refractory duodenal ulcer
| Autor: | M. Donatelli, M.G. Cataldo, D. Brancato |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Pharmacology
medicine.medical_specialty Chemotherapy business.industry medicine.medical_treatment Gastroenterology Group B Ranitidine Duodenal ulcer medicine.anatomical_structure Histamine H2 receptor Refractory Internal medicine Duodenum medicine Roxatidine acetate Pharmacology (medical) business medicine.drug |
| Zdroj: | Current Therapeutic Research. 55:438-445 |
| ISSN: | 0011-393X |
| DOI: | 10.1016/s0011-393x(05)80530-2 |
| Popis: | Fourteen patients with duodenal ulcer not healed after treatment with ranitidine at the standard dosage of 300 mg/day for 12 weeks were enrolled in the study. Eight patients were treated with roxatidine acetate, 150 mg/day, for 8 weeks (group A); six patients received treatment with ranitidine, 600 mg/day, for 8 weeks (group B). Efficacy of treatment was evaluated on the basis of reduction of ulcer pain, lowering of maximal acid output (MAO) levels, and cicatrization of ulcer lesion. The patients treated with roxatidine showed a significant reduction in MAO levels after 4 weeks, whereas the patients treated with ranitidine showed a significant reduction in MAO levels after 8 weeks. The differences in reduction of ulcer pain or cicatrization percentage were not significant between groups. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|